Checkpoint Therapeutics, Inc. (CKPT)
| Market Cap | 124.25M |
| Revenue (ttm) | 252,000 |
| Net Income (ttm) | -67.01M |
| Shares Out | 91.03M |
| EPS (ttm) | -0.75 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 174,956 |
| Open | 1.44 |
| Previous Close | 1.44 |
| Day's Range | 1.36 - 1.45 |
| 52-Week Range | 0.96 - 4.64 |
| Beta | 1.63 |
| Analysts | Buy |
| Price Target | 20.20 (+1,379.9%) |
| Earnings Date | May 12, 2022 |
About CKPT
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger...
Financial Performance
In 2021, CKPT's revenue was $268,000, a decrease of -74.93% compared to the previous year's $1.07 million. Losses were -$56.67 million, 145.5% more than in 2020.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for CKPT stock is "Buy." The 12-month stock price forecast is 20.2, which is an increase of 1,379.85% from the latest price.
News
Checkpoint Therapeutics Receives Pediatric Investigational Plan Waivers for Cosibelimab from the European Medicines A...
Waivers remove requirement to conduct pediatric clinical studies to support cosibelimab marketing authorization applications in Europe Waivers remove requirement to conduct pediatric clinical studies to...
Checkpoint Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Highlights
Positive top-line results from registration-enabling study of cosibelimab in metastatic cutaneous squamous cell carcinoma announced in January 2022; BLA submission expected in 2022 Positive top-line res...
Checkpoint Therapeutics Announces Data Presentation of Pivotal Trial Results of Cosibelimab to be Presented at the 20...
WALTHAM, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that the res...
Insiders Are Dumping These Penny Stocks, Look Out Below Or Buy The Dip?
Time to sell these penny stocks? The post Insiders Are Dumping These Penny Stocks, Look Out Below Or Buy The Dip?
Checkpoint Therapeutics to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities
WALTHAM, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that members...
Checkpoint Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Highlights
WALTHAM, Mass., March 28, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial re...
2 Biotech Stocks That Could Be 10-Baggers in 2022
These two clinical-stage biotechs have major upcoming catalysts that could catapult their shares higher.
Checkpoint Therapeutics to Participate in the B. Riley Securities' Virtual Oncology Conference
WALTHAM, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Ol...
Checkpoint Therapeutics' Cosibelimab Posts 47.4% ORR In Skin Cancer Patients
Checkpoint Therapeutics Inc (NASDAQ: CKPT) announced topline results from its registration-enabling clinical trial evaluating cosibelimab, administered as a fixed dose of 800 mg every two weeks in patie...
Why Checkpoint Therapeutics Stock Is Heating Up Today
Based on its latest clinical trial data, this small-cap biotech could have a best-in-class treatment for advanced skin cancer on the way.
Checkpoint Therapeutics Announces Positive Topline Results from the Registration-Enabling Trial of Cosibelimab in Met...
WALTHAM, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced positive topl...
Checkpoint Therapeutics Announces Initiation of CONTERNO Phase 3 Trial of Cosibelimab Combined with Chemotherapy in P...
WALTHAM, Mass., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the initiatio...
Checkpoint Therapeutics Reports Third Quarter 2021 Financial Results
WALTHAM, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial res...
Checkpoint Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference
WALTHAM, Mass., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James O...
Checkpoint Therapeutics to Participate in Two Upcoming Investor Conferences
WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James O...
Checkpoint Therapeutics Reports Second Quarter 2021 Financial Results
NEW YORK, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results f...
Checkpoint Therapeutics to Participate in the Ladenburg Thalmann 2021 Healthcare Conference
NEW YORK, July 08, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero...
Why Checkpoint Therapeutics Skyrocketed Today
One analyst becomes a fervent believer in the company's stock.
Checkpoint Therapeutics Announces Completion of Enrollment in the Registration-Enabling Trial of Cosibelimab in Metas...
NEW YORK, May 12, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the completion of en...
4 Meme Penny Stocks To Watch As DogeCoin Rises
Meme penny stocks are a budding sector; have you heard of these 4? The post 4 Meme Penny Stocks To Watch As DogeCoin Rises appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStock...
Checkpoint Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate Highlights
NEW YORK, May 06, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results fo...
Checkpoint Therapeutics Reports Full-Year 2020 Financial Results and Recent Corporate Highlights
NEW YORK, March 09, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results ...
Checkpoint Therapeutics Announces Formation of Scientific Advisory Board
Members include preeminent clinical and scientific thought leaders in oncology Members include preeminent clinical and scientific thought leaders in oncology
Checkpoint Therapeutics to Participate in Three January 2021 Virtual Investor Conferences
NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero...